Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study
Journal of Clinical Oncology Dec 10, 2018
Owonikoko TK, et al. - Researchers assessed the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage small-cell lung cancer (ES-SCLC). They assessed progression-free survival (PFS) in ES-SCLC patients who were randomly administered four 3-week cycles of CE (75 mg/m2 intravenously on day 1 and 100 mg/m2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). These patients were stratified by sex and serum lactate dehydrogenase levels. In patients with ES-SCLC, signal of efficacy was observed following addition of veliparib to frontline chemotherapy and prespecified end point was met.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries